Jeito Capital leads a $67.5 million Series B financing round to support XyloCor Therapeutics in advancing innovative gene therapies for cardiovascular disease.
Information on the Target
Founded in 2019, XyloCor Therapeutics is a clinical-stage biopharmaceutical company based in the United States that focuses on developing innovative gene therapies specifically targeting cardiovascular diseases. With pioneering advancements in one-time gene therapy approaches, XyloCor aims to address critical unmet needs in treating underserved patient populations suffering from severe cardiovascular conditions.
The company’s lead therapeutic candidate, XC001 (encoberminogene rezmadenovec), is currently being evaluated in clinical trials. This novel gene therapy is designed to enhance blood flow and alleviate symptoms for patients suffering from refractory angina, providing a much-needed solution for those whose quality of life has been severely impacted by their conditions.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview
The biopharmaceutical sector in the United States is a leader in research and development, particularly in the context of innovative therapies for chronic diseases. Cardiovascular diseases remain the leadin
Similar Deals
Kurma Growth Opportunities Fund → NUCLIDIUM
2025
Jeito Capital
invested in
XyloCor Therapeutics
in 2025
in a Series B deal
Disclosed details
Transaction Size: $68M